This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-106b-3p | ERGIC1 | -1.02 | 0.00426 | 0.69 | 0.70545 | miRNAWalker2 validate | -0.12 | 0.01045 | ||
2 | hsa-miR-106b-3p | KIAA0232 | -1.02 | 0.00426 | 0.91 | 0.62378 | miRNAWalker2 validate | -0.11 | 0.02715 | ||
3 | hsa-miR-106b-3p | MTMR3 | -1.02 | 0.00426 | 0.19 | 0.92739 | miRNAWalker2 validate | -0.1 | 0.03283 | ||
4 | hsa-miR-106b-3p | PRDM2 | -1.02 | 0.00426 | 0.14 | 0.93526 | miRNAWalker2 validate | -0.09 | 0.04098 | ||
5 | hsa-miR-106b-3p | SH3BP4 | -1.02 | 0.00426 | 1.12 | 0.53932 | miRNAWalker2 validate | -0.27 | 0.00402 | ||
6 | hsa-miR-106b-3p | UQCR11 | -1.02 | 0.00426 | 0.4 | 0.86485 | miRNAWalker2 validate | -0.09 | 0.009 | ||
7 | hsa-miR-149-5p | AGO1 | 3.12 | 0.01101 | -0.27 | 0.874 | miRNAWalker2 validate | -0.06 | 0.0004 | ||
8 | hsa-miR-149-5p | ALYREF | 3.12 | 0.01101 | -0.85 | 0.697 | miRNAWalker2 validate | -0.09 | 0.03688 | ||
9 | hsa-miR-149-5p | ARPC2 | 3.12 | 0.01101 | -0.46 | 0.87458 | miRNAWalker2 validate | -0.07 | 0.00504 | ||
10 | hsa-miR-149-5p | ARRB2 | 3.12 | 0.01101 | -0.52 | 0.80444 | miRNAWalker2 validate | -0.08 | 0.01559 | ||
11 | hsa-miR-149-5p | ATAD3A | 3.12 | 0.01101 | -1.1 | 0.5997 | miRNAWalker2 validate | -0.19 | 0 | ||
12 | hsa-miR-149-5p | BID | 3.12 | 0.01101 | -0.72 | 0.72083 | miRNAWalker2 validate | -0.14 | 1.0E-5 | ||
13 | hsa-miR-149-5p | BIRC5 | 3.12 | 0.01101 | -1.75 | 0.47362 | miRNAWalker2 validate | -0.17 | 0.02877 | ||
14 | hsa-miR-149-5p | CALD1 | 3.12 | 0.01101 | -0.32 | 0.86115 | miRNAWalker2 validate | -0.07 | 0.00744 | ||
15 | hsa-miR-149-5p | CALR | 3.12 | 0.01101 | -0.64 | 0.76691 | miRNAWalker2 validate | -0.12 | 0 | ||
16 | hsa-miR-149-5p | CBS | 3.12 | 0.01101 | -2.31 | 0.24372 | miRNAWalker2 validate | -0.34 | 0.00023 | ||
17 | hsa-miR-149-5p | CCT4 | 3.12 | 0.01101 | -0.42 | 0.84686 | miRNAWalker2 validate | -0.07 | 0.00011 | ||
18 | hsa-miR-149-5p | CCT6A | 3.12 | 0.01101 | -0.51 | 0.83643 | miRNAWalker2 validate | -0.08 | 0.00684 | ||
19 | hsa-miR-149-5p | CDK5RAP2 | 3.12 | 0.01101 | -0.11 | 0.9552 | miRNAWalker2 validate | -0.06 | 0.04039 | ||
20 | hsa-miR-149-5p | CSTF2 | 3.12 | 0.01101 | -0.21 | 0.917 | miRNAWalker2 validate | -0.07 | 0.00593 | ||
21 | hsa-miR-149-5p | DCUN1D5 | 3.12 | 0.01101 | -0.48 | 0.84297 | miRNAWalker2 validate | -0.14 | 7.0E-5 | ||
22 | hsa-miR-149-5p | DDT | 3.12 | 0.01101 | -0.31 | 0.90377 | miRNAWalker2 validate | -0.1 | 0.00223 | ||
23 | hsa-miR-149-5p | DESI1 | 3.12 | 0.01101 | -0.26 | 0.86664 | miRNAWalker2 validate | -0.05 | 0.01396 | ||
24 | hsa-miR-149-5p | DGCR14 | 3.12 | 0.01101 | -0.2 | 0.91191 | miRNAWalker2 validate | -0.06 | 0.00259 | ||
25 | hsa-miR-149-5p | E2F3 | 3.12 | 0.01101 | -1.39 | 0.53069 | miRNAWalker2 validate | -0.26 | 0 | ||
26 | hsa-miR-149-5p | ETS2 | 3.12 | 0.01101 | -0.53 | 0.76747 | miRNAWalker2 validate | -0.13 | 0 | ||
27 | hsa-miR-149-5p | FOXM1 | 3.12 | 0.01101 | -2.01 | 0.25686 | miRNAWalker2 validate; MirTarget | -0.19 | 0.0054 | 25613903; 25613903; 25613903; 25613903 | MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1;The study further explored whether miR-149 inhibits migration and invasion of CRC cells by targeting the mammalian Forkhead Box M1 FOXM1 miR-149 was significantly downregulated in CRC tissues and low miR-149 expression was observed to be significantly correlated with lymph node or distant metastasis and advanced TNM stage of CRC patients;Gain- and loss - of - function assays indicated that miR-149 significantly inhibited growth migration and invasion of CRC cells by targeting FOXM1;Furthermore FOXM1 was significantly uiregulated in CRC tissues and inversely correlated with miR-149 expression |
28 | hsa-miR-149-5p | FZD5 | 3.12 | 0.01101 | -0.39 | 0.8106 | miRNAWalker2 validate; miRNATAP | -0.08 | 0.00898 | ||
29 | hsa-miR-149-5p | GAPDH | 3.12 | 0.01101 | -1.02 | 0.72664 | miRNAWalker2 validate | -0.12 | 0.00533 | ||
30 | hsa-miR-149-5p | GFPT2 | 3.12 | 0.01101 | -0.57 | 0.76823 | miRNAWalker2 validate | -0.1 | 0.04492 | ||
31 | hsa-miR-149-5p | GPI | 3.12 | 0.01101 | -0.76 | 0.78548 | miRNAWalker2 validate | -0.14 | 0.0003 | ||
32 | hsa-miR-149-5p | HDAC2 | 3.12 | 0.01101 | -0.85 | 0.7371 | miRNAWalker2 validate | -0.15 | 0.00021 | ||
33 | hsa-miR-149-5p | HUWE1 | 3.12 | 0.01101 | -0.15 | 0.92966 | miRNAWalker2 validate | -0.05 | 0.0384 | ||
34 | hsa-miR-149-5p | IFI30 | 3.12 | 0.01101 | -1.05 | 0.7115 | miRNAWalker2 validate | -0.15 | 0.00327 | ||
35 | hsa-miR-149-5p | ILF2 | 3.12 | 0.01101 | -0.79 | 0.77486 | miRNAWalker2 validate | -0.12 | 0.00071 | ||
36 | hsa-miR-149-5p | ILF3 | 3.12 | 0.01101 | -0.35 | 0.87155 | miRNAWalker2 validate | -0.06 | 0.00979 | ||
37 | hsa-miR-149-5p | KHSRP | 3.12 | 0.01101 | -0.48 | 0.80954 | miRNAWalker2 validate | -0.11 | 0 | ||
38 | hsa-miR-149-5p | KIF1A | 3.12 | 0.01101 | -0.72 | 0.61239 | miRNAWalker2 validate | -0.08 | 0.00804 | ||
39 | hsa-miR-149-5p | KIF1C | 3.12 | 0.01101 | -0.2 | 0.93859 | miRNAWalker2 validate | -0.06 | 0.04994 | ||
40 | hsa-miR-149-5p | KLHDC3 | 3.12 | 0.01101 | -0.82 | 0.65391 | miRNAWalker2 validate | -0.1 | 0.00063 | ||
41 | hsa-miR-149-5p | LGI2 | 3.12 | 0.01101 | -0.36 | 0.8085 | miRNAWalker2 validate | -0.07 | 0.03394 | ||
42 | hsa-miR-149-5p | LRRC42 | 3.12 | 0.01101 | -0.5 | 0.80034 | miRNAWalker2 validate | -0.07 | 0.02077 | ||
43 | hsa-miR-149-5p | LRRC8A | 3.12 | 0.01101 | -0.19 | 0.92453 | miRNAWalker2 validate | -0.06 | 0.0213 | ||
44 | hsa-miR-149-5p | MID1 | 3.12 | 0.01101 | -1.02 | 0.50335 | miRNAWalker2 validate | -0.18 | 0 | ||
45 | hsa-miR-149-5p | MRPS25 | 3.12 | 0.01101 | -0.76 | 0.76197 | miRNAWalker2 validate | -0.15 | 9.0E-5 | ||
46 | hsa-miR-149-5p | MYH9 | 3.12 | 0.01101 | -0.36 | 0.876 | miRNAWalker2 validate; miRNATAP | -0.09 | 0.03062 | ||
47 | hsa-miR-149-5p | NAT10 | 3.12 | 0.01101 | -0.55 | 0.79117 | miRNAWalker2 validate | -0.07 | 0.0371 | ||
48 | hsa-miR-149-5p | NECAP2 | 3.12 | 0.01101 | -0.55 | 0.78305 | miRNAWalker2 validate | -0.06 | 0.01401 | ||
49 | hsa-miR-149-5p | NOC2L | 3.12 | 0.01101 | -0.28 | 0.87992 | miRNAWalker2 validate | -0.06 | 0.01517 | ||
50 | hsa-miR-149-5p | NONO | 3.12 | 0.01101 | -0.17 | 0.94156 | miRNAWalker2 validate; miRNATAP | -0.08 | 0.00149 | ||
51 | hsa-miR-149-5p | PABPC1 | 3.12 | 0.01101 | -0.57 | 0.84703 | miRNAWalker2 validate | -0.08 | 0.01905 | ||
52 | hsa-miR-149-5p | PLEKHO1 | 3.12 | 0.01101 | -0.72 | 0.78249 | miRNAWalker2 validate | -0.11 | 0.00364 | ||
53 | hsa-miR-149-5p | PLOD1 | 3.12 | 0.01101 | -1.31 | 0.54879 | miRNAWalker2 validate | -0.22 | 0 | ||
54 | hsa-miR-149-5p | PLSCR3 | 3.12 | 0.01101 | -0.24 | 0.92576 | miRNAWalker2 validate | -0.06 | 0.03718 | ||
55 | hsa-miR-149-5p | POLR3D | 3.12 | 0.01101 | -0.76 | 0.68386 | miRNAWalker2 validate | -0.12 | 0.00017 | ||
56 | hsa-miR-149-5p | PSMD8 | 3.12 | 0.01101 | -0.37 | 0.85839 | miRNAWalker2 validate | -0.06 | 0.00436 | ||
57 | hsa-miR-149-5p | PTPRK | 3.12 | 0.01101 | -1 | 0.68703 | miRNAWalker2 validate; miRNATAP | -0.19 | 0.00123 | ||
58 | hsa-miR-149-5p | RFC2 | 3.12 | 0.01101 | -0.64 | 0.7343 | miRNAWalker2 validate | -0.06 | 0.04158 | ||
59 | hsa-miR-149-5p | RPL18A | 3.12 | 0.01101 | -0.55 | 0.85221 | miRNAWalker2 validate | -0.1 | 0.00213 | ||
60 | hsa-miR-149-5p | RRP1 | 3.12 | 0.01101 | -1 | 0.62052 | miRNAWalker2 validate | -0.13 | 4.0E-5 | ||
61 | hsa-miR-149-5p | SBF1 | 3.12 | 0.01101 | -0.53 | 0.77898 | miRNAWalker2 validate | -0.09 | 0.00351 | ||
62 | hsa-miR-149-5p | SDC1 | 3.12 | 0.01101 | -0.58 | 0.79473 | miRNAWalker2 validate | -0.13 | 0.01316 | 25462564; 25462564; 25462564; 25462564 | In this study we examined the expression of miRNA-126 miR-126 and miR-149 in prostate cancer and investigated the molecular mechanisms by which they affect syndecan-1 in prostate cancer;After silencing syndecan-1 miR-126 and/or miR-149 in the PC3 cells cell proliferation senescence and p21 induction were assessed using the MTS assay senescence-associated β-galactosidase SA-β-Gal assay and immunocytochemistry respectively;When syndecan-1 was silenced the PC3 cells showed reduced expression of miR-126 and miR-149 most effectively;Our results suggest that miR-126 and miR-149 are associated with the expression of syndecan-1 in prostate cancer cells |
63 | hsa-miR-149-5p | SKI | 3.12 | 0.01101 | -0.21 | 0.89675 | miRNAWalker2 validate | -0.06 | 0.0178 | ||
64 | hsa-miR-149-5p | SLC2A1 | 3.12 | 0.01101 | -1.17 | 0.59376 | miRNAWalker2 validate | -0.14 | 0.01618 | ||
65 | hsa-miR-149-5p | SMCHD1 | 3.12 | 0.01101 | -0.44 | 0.79105 | miRNAWalker2 validate | -0.06 | 0.00089 | ||
66 | hsa-miR-149-5p | STAG1 | 3.12 | 0.01101 | -0.38 | 0.8033 | miRNAWalker2 validate | -0.07 | 0.0045 | ||
67 | hsa-miR-149-5p | SUPT5H | 3.12 | 0.01101 | -0.51 | 0.81165 | miRNAWalker2 validate | -0.09 | 0.00033 | ||
68 | hsa-miR-149-5p | TCF20 | 3.12 | 0.01101 | -0.46 | 0.81731 | miRNAWalker2 validate | -0.11 | 0.00173 | ||
69 | hsa-miR-149-5p | TKT | 3.12 | 0.01101 | -0.77 | 0.76912 | miRNAWalker2 validate | -0.18 | 0 | ||
70 | hsa-miR-149-5p | TRIP6 | 3.12 | 0.01101 | -1.13 | 0.63776 | miRNAWalker2 validate | -0.18 | 0.00149 | ||
71 | hsa-miR-149-5p | TTL | 3.12 | 0.01101 | -0.34 | 0.81147 | miRNAWalker2 validate | -0.05 | 5.0E-5 | ||
72 | hsa-miR-149-5p | YARS2 | 3.12 | 0.01101 | -0.36 | 0.85396 | miRNAWalker2 validate | -0.07 | 0.00071 | ||
73 | hsa-miR-149-5p | YBX1 | 3.12 | 0.01101 | -1.79 | 0.45477 | miRNAWalker2 validate | -0.28 | 0 | ||
74 | hsa-miR-149-5p | YTHDF1 | 3.12 | 0.01101 | -0.13 | 0.9531 | miRNAWalker2 validate | -0.06 | 0.02397 | ||
75 | hsa-miR-149-5p | ZNF276 | 3.12 | 0.01101 | -0.36 | 0.84885 | miRNAWalker2 validate | -0.08 | 0.00115 | ||
76 | hsa-miR-26b-5p | LY6D | 1.08 | 0.63865 | -3.07 | 0.04745 | miRNAWalker2 validate | -0.6 | 0.00053 | ||
77 | hsa-miR-26b-5p | PSAT1 | 1.08 | 0.63865 | -3.67 | 0.0491 | miRNAWalker2 validate | -0.76 | 8.0E-5 | ||
78 | hsa-miR-29b-2-5p | ZC3H18 | 1.52 | 4.0E-5 | -0.77 | 0.66808 | miRNAWalker2 validate | -0.12 | 0.04288 | ||
79 | hsa-miR-335-5p | ART3 | 1.07 | 0.43467 | -3.13 | 0.02758 | miRNAWalker2 validate | -0.29 | 0.01873 | ||
80 | hsa-miR-33b-5p | ABCA1 | 0.86 | 0.01091 | -0.19 | 0.90294 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.07 | 0.00466 | ||
81 | hsa-miR-342-3p | PSAT1 | 1.94 | 0.35273 | -3.67 | 0.0491 | miRNAWalker2 validate | -0.91 | 0 | ||
82 | hsa-miR-375 | FOLR1 | 3.32 | 0.05354 | -3.7 | 0.04664 | miRNAWalker2 validate | -0.31 | 0.00039 | ||
83 | hsa-miR-449a | CDK6 | 3.28 | 0.00386 | -1.38 | 0.41289 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.08 | 0.00114 | ||
84 | hsa-miR-449a | HDAC1 | 3.28 | 0.00386 | -0.15 | 0.95136 | miRNAWalker2 validate; miRTarBase; miRanda; miRNATAP | -0.05 | 0.00607 | ||
85 | hsa-miR-449a | MET | 3.28 | 0.00386 | -0.96 | 0.53603 | miRNAWalker2 validate; miRTarBase; PITA; miRanda | -0.06 | 0.00126 | ||
86 | hsa-miR-519a-3p | DICER1 | -2.74 | 0 | 0.4 | 0.81404 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.07 | 0.01605 | ||
87 | hsa-miR-9-5p | ACADSB | -3.36 | 1.0E-5 | 2.24 | 0.20859 | miRNAWalker2 validate | -0.32 | 0 | ||
88 | hsa-miR-9-5p | APBB2 | -3.36 | 1.0E-5 | 1.71 | 0.40498 | miRNAWalker2 validate | -0.26 | 0 | ||
89 | hsa-miR-9-5p | AUH | -3.36 | 1.0E-5 | 0.44 | 0.82384 | miRNAWalker2 validate; miRNATAP | -0.08 | 0.0051 | ||
90 | hsa-miR-9-5p | BIK | -3.36 | 1.0E-5 | 1.65 | 0.43724 | miRNAWalker2 validate | -0.19 | 0.00125 | ||
91 | hsa-miR-9-5p | BOD1L1 | -3.36 | 1.0E-5 | 0.46 | 0.77608 | miRNAWalker2 validate | -0.05 | 0.01144 | ||
92 | hsa-miR-9-5p | CCND1 | -3.36 | 1.0E-5 | 1.75 | 0.38407 | miRNAWalker2 validate | -0.26 | 0.00015 | ||
93 | hsa-miR-9-5p | CCNDBP1 | -3.36 | 1.0E-5 | 0.59 | 0.80812 | miRNAWalker2 validate; MirTarget | -0.15 | 0.00024 | ||
94 | hsa-miR-9-5p | CCNG1 | -3.36 | 1.0E-5 | 0.32 | 0.86825 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.1 | 0.00257 | ||
95 | hsa-miR-9-5p | CERS2 | -3.36 | 1.0E-5 | 0.99 | 0.69052 | miRNAWalker2 validate | -0.13 | 0.00229 | ||
96 | hsa-miR-9-5p | CERS4 | -3.36 | 1.0E-5 | 1.7 | 0.40661 | miRNAWalker2 validate | -0.26 | 0 | ||
97 | hsa-miR-9-5p | COL12A1 | -3.36 | 1.0E-5 | 1.31 | 0.54066 | miRNAWalker2 validate; miRNATAP | -0.19 | 0.0031 | ||
98 | hsa-miR-9-5p | COLEC12 | -3.36 | 1.0E-5 | 0.97 | 0.60644 | miRNAWalker2 validate | -0.21 | 0.00032 | ||
99 | hsa-miR-9-5p | CXXC5 | -3.36 | 1.0E-5 | 1.93 | 0.41517 | miRNAWalker2 validate | -0.31 | 0 | ||
100 | hsa-miR-9-5p | DMXL1 | -3.36 | 1.0E-5 | 0.33 | 0.83576 | miRNAWalker2 validate | -0.06 | 3.0E-5 | ||
101 | hsa-miR-9-5p | FLNB | -3.36 | 1.0E-5 | 0.93 | 0.61409 | miRNAWalker2 validate | -0.1 | 0.03825 | ||
102 | hsa-miR-9-5p | FSTL3 | -3.36 | 1.0E-5 | 0.87 | 0.61901 | miRNAWalker2 validate | -0.13 | 0.00036 | ||
103 | hsa-miR-9-5p | HN1L | -3.36 | 1.0E-5 | 0.82 | 0.67924 | miRNAWalker2 validate; MirTarget | -0.07 | 0.02072 | ||
104 | hsa-miR-9-5p | MCC | -3.36 | 1.0E-5 | 0.59 | 0.70325 | miRNAWalker2 validate; MirTarget | -0.12 | 0.00066 | ||
105 | hsa-miR-9-5p | NBEA | -3.36 | 1.0E-5 | 1.36 | 0.44369 | miRNAWalker2 validate | -0.23 | 0 | ||
106 | hsa-miR-9-5p | NRIP3 | -3.36 | 1.0E-5 | 0.91 | 0.5323 | miRNAWalker2 validate | -0.16 | 0.00374 | ||
107 | hsa-miR-9-5p | PDZK1 | -3.36 | 1.0E-5 | 2 | 0.23291 | miRNAWalker2 validate | -0.27 | 0.01588 | ||
108 | hsa-miR-9-5p | PIGB | -3.36 | 1.0E-5 | 0.47 | 0.79037 | miRNAWalker2 validate | -0.12 | 0 | ||
109 | hsa-miR-9-5p | PQLC3 | -3.36 | 1.0E-5 | 0.35 | 0.86246 | miRNAWalker2 validate | -0.11 | 0.00192 | ||
110 | hsa-miR-9-5p | RASSF8 | -3.36 | 1.0E-5 | 0.26 | 0.85724 | miRNAWalker2 validate | -0.05 | 0.02943 | ||
111 | hsa-miR-9-5p | SLC22A5 | -3.36 | 1.0E-5 | 1.7 | 0.41158 | miRNAWalker2 validate | -0.21 | 0.00019 | ||
112 | hsa-miR-9-5p | SLC35E2 | -3.36 | 1.0E-5 | 0.57 | 0.72641 | miRNAWalker2 validate | -0.09 | 0.0001 | ||
113 | hsa-miR-9-5p | SYPL1 | -3.36 | 1.0E-5 | 0.06 | 0.97603 | miRNAWalker2 validate | -0.08 | 0.0233 | ||
114 | hsa-miR-9-5p | TBC1D9 | -3.36 | 1.0E-5 | 3.79 | 0.09601 | miRNAWalker2 validate | -0.55 | 0 | ||
115 | hsa-miR-9-5p | TESK2 | -3.36 | 1.0E-5 | 0.43 | 0.79616 | miRNAWalker2 validate; MirTarget | -0.11 | 0.00192 | ||
116 | hsa-miR-9-5p | UGDH | -3.36 | 1.0E-5 | 1.28 | 0.50259 | miRNAWalker2 validate | -0.21 | 1.0E-5 | ||
117 | hsa-miR-9-5p | AP3B1 | -3.36 | 1.0E-5 | 0.32 | 0.88621 | miRTarBase | -0.07 | 0.00384 | ||
118 | hsa-miR-10a-3p | APCDD1L | 1.42 | 0.03159 | -1.1 | 0.44769 | MirTarget; miRNATAP | -0.1 | 0.0358 | ||
119 | hsa-miR-135a-5p | MMP11 | 1.16 | 0.04954 | 1.45 | 0.57829 | MirTarget | -0.19 | 0.04628 | ||
120 | hsa-miR-135a-5p | MXRA5 | 1.16 | 0.04954 | 0.49 | 0.81283 | MirTarget | -0.14 | 0.01756 | ||
121 | hsa-miR-135a-5p | SPSB1 | 1.16 | 0.04954 | -0.61 | 0.7487 | MirTarget | -0.1 | 0.00586 | ||
122 | hsa-miR-135a-5p | ACTR3B | 1.16 | 0.04954 | -1.01 | 0.575 | MirTarget | -0.09 | 0.01113 | ||
123 | hsa-miR-135a-5p | NET1 | 1.16 | 0.04954 | 0.13 | 0.95885 | MirTarget; miRNATAP | -0.12 | 0.01563 | ||
124 | hsa-miR-135a-5p | ANGPTL2 | 1.16 | 0.04954 | 0.27 | 0.89589 | MirTarget; miRNATAP | -0.1 | 0.0187 | ||
125 | hsa-miR-135a-5p | NAP1L2 | 1.16 | 0.04954 | 0.06 | 0.9685 | MirTarget | -0.07 | 0.04451 | ||
126 | hsa-miR-135a-5p | PRKD3 | 1.16 | 0.04954 | -0.85 | 0.59962 | MirTarget; miRNATAP | -0.07 | 0.00131 | ||
127 | hsa-miR-135a-5p | ANKRD33B | 1.16 | 0.04954 | -0.23 | 0.87543 | MirTarget | -0.06 | 0.04951 | ||
128 | hsa-miR-135a-5p | VASH2 | 1.16 | 0.04954 | -0.78 | 0.64495 | MirTarget | -0.15 | 0.0035 | ||
129 | hsa-miR-135a-5p | PDP1 | 1.16 | 0.04954 | 0.2 | 0.90854 | MirTarget | -0.1 | 0.02374 | ||
130 | hsa-miR-135a-5p | CDR2L | 1.16 | 0.04954 | -0.26 | 0.90304 | MirTarget | -0.09 | 0.02769 | ||
131 | hsa-miR-135a-5p | TMEM97 | 1.16 | 0.04954 | 0.08 | 0.96335 | MirTarget; miRNATAP | -0.11 | 0.02473 | ||
132 | hsa-miR-135a-5p | STMN1 | 1.16 | 0.04954 | -0.8 | 0.69766 | MirTarget | -0.06 | 0.03766 | ||
133 | hsa-miR-135a-5p | PATL1 | 1.16 | 0.04954 | -0.53 | 0.75764 | MirTarget; miRNATAP | -0.06 | 0.01169 | ||
134 | hsa-miR-135a-5p | TCF19 | 1.16 | 0.04954 | -0.76 | 0.60532 | MirTarget | -0.05 | 0.04908 | ||
135 | hsa-miR-135a-5p | FOXN2 | 1.16 | 0.04954 | -0.74 | 0.6739 | MirTarget; miRNATAP | -0.14 | 0.00152 | ||
136 | hsa-miR-135a-5p | CREG1 | 1.16 | 0.04954 | -0.86 | 0.71445 | MirTarget; miRNATAP | -0.08 | 0.04172 | ||
137 | hsa-miR-135a-5p | RASAL2 | 1.16 | 0.04954 | -0.58 | 0.73449 | MirTarget | -0.09 | 0.00053 | ||
138 | hsa-miR-135a-5p | KIAA1549L | 1.16 | 0.04954 | -1.39 | 0.4114 | MirTarget | -0.17 | 0.00546 | ||
139 | hsa-miR-135a-5p | SSR2 | 1.16 | 0.04954 | -0.1 | 0.96778 | MirTarget | -0.07 | 0.0008 | ||
140 | hsa-miR-135a-5p | MEGF6 | 1.16 | 0.04954 | 0.28 | 0.88433 | MirTarget | -0.08 | 0.04783 | ||
141 | hsa-miR-135a-5p | TLDC1 | 1.16 | 0.04954 | -1.29 | 0.50131 | MirTarget | -0.13 | 0.00251 | ||
142 | hsa-miR-135a-5p | FOXN3 | 1.16 | 0.04954 | -0.35 | 0.87262 | MirTarget; miRNATAP | -0.07 | 0.02285 | ||
143 | hsa-miR-135b-5p | MMP11 | -4.4 | 0.00013 | 1.45 | 0.57829 | MirTarget | -0.16 | 0.02244 | ||
144 | hsa-miR-135b-5p | NBEA | -4.4 | 0.00013 | 1.36 | 0.44369 | MirTarget | -0.12 | 0.00066 | ||
145 | hsa-miR-135b-5p | TMEM9 | -4.4 | 0.00013 | 0.59 | 0.79731 | MirTarget | -0.06 | 0.04842 | ||
146 | hsa-miR-135b-5p | SLC24A2 | -4.4 | 0.00013 | 0.65 | 0.65684 | MirTarget | -0.06 | 0.00408 | ||
147 | hsa-miR-135b-5p | SC5D | -4.4 | 0.00013 | 0.43 | 0.8288 | MirTarget | -0.08 | 0.03405 | ||
148 | hsa-miR-135b-5p | SETD7 | -4.4 | 0.00013 | 0.25 | 0.87589 | MirTarget; mirMAP | -0.05 | 8.0E-5 | ||
149 | hsa-miR-135b-5p | MYO6 | -4.4 | 0.00013 | 1.23 | 0.60133 | MirTarget | -0.11 | 0.00129 | ||
150 | hsa-miR-135b-5p | PSD3 | -4.4 | 0.00013 | 1.86 | 0.28381 | MirTarget; mirMAP | -0.19 | 0.00132 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | REGULATION OF CELL DIFFERENTIATION | 224 | 1492 | 4.525e-19 | 2.105e-15 |
2 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 197 | 1275 | 3.694e-18 | 8.595e-15 |
3 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 237 | 1672 | 4.781e-17 | 7.415e-14 |
4 | REGULATION OF CELL DEVELOPMENT | 138 | 836 | 3.208e-15 | 3.732e-12 |
5 | LOCOMOTION | 169 | 1114 | 6.496e-15 | 6.045e-12 |
6 | POSITIVE REGULATION OF GENE EXPRESSION | 232 | 1733 | 7.116e-14 | 4.426e-11 |
7 | CELL MOTILITY | 134 | 835 | 7.609e-14 | 4.426e-11 |
8 | LOCALIZATION OF CELL | 134 | 835 | 7.609e-14 | 4.426e-11 |
9 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 239 | 1805 | 9.39e-14 | 4.855e-11 |
10 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 126 | 771 | 1.167e-13 | 5.428e-11 |
11 | INTRACELLULAR SIGNAL TRANSDUCTION | 213 | 1572 | 2.677e-13 | 1.132e-10 |
12 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 167 | 1152 | 5.34e-13 | 2.07e-10 |
13 | REGULATION OF NEURON DIFFERENTIATION | 98 | 554 | 6.183e-13 | 2.213e-10 |
14 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 165 | 1142 | 9.898e-13 | 3.29e-10 |
15 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 120 | 750 | 2.021e-12 | 6.27e-10 |
16 | CELL DEVELOPMENT | 194 | 1426 | 2.498e-12 | 7.264e-10 |
17 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 128 | 823 | 2.762e-12 | 7.56e-10 |
18 | RESPONSE TO ENDOGENOUS STIMULUS | 193 | 1450 | 2.048e-11 | 5.295e-09 |
19 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 214 | 1656 | 2.391e-11 | 5.855e-09 |
20 | REGULATION OF CELL PROLIFERATION | 196 | 1496 | 5.685e-11 | 1.323e-08 |
21 | TISSUE DEVELOPMENT | 198 | 1518 | 6.621e-11 | 1.467e-08 |
22 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 74 | 408 | 1.347e-10 | 2.849e-08 |
23 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 113 | 740 | 1.741e-10 | 3.523e-08 |
24 | NEUROGENESIS | 184 | 1402 | 2.065e-10 | 4.003e-08 |
25 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 182 | 1395 | 4.231e-10 | 7.875e-08 |
26 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 117 | 788 | 4.713e-10 | 8.122e-08 |
27 | CIRCULATORY SYSTEM DEVELOPMENT | 117 | 788 | 4.713e-10 | 8.122e-08 |
28 | IMMUNE SYSTEM PROCESS | 241 | 1984 | 5.329e-10 | 8.265e-08 |
29 | PROTEIN PHOSPHORYLATION | 134 | 944 | 5.213e-10 | 8.265e-08 |
30 | VASCULATURE DEVELOPMENT | 80 | 469 | 5.191e-10 | 8.265e-08 |
31 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 221 | 1784 | 5.585e-10 | 8.383e-08 |
32 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 140 | 1004 | 7.08e-10 | 9.983e-08 |
33 | POSITIVE REGULATION OF CELL DEVELOPMENT | 80 | 472 | 7.076e-10 | 9.983e-08 |
34 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 221 | 1791 | 7.937e-10 | 1.086e-07 |
35 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 193 | 1517 | 9.606e-10 | 1.277e-07 |
36 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 39 | 162 | 1.043e-09 | 1.349e-07 |
37 | CELLULAR COMPONENT MORPHOGENESIS | 128 | 900 | 1.151e-09 | 1.447e-07 |
38 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 141 | 1021 | 1.182e-09 | 1.447e-07 |
39 | NEGATIVE REGULATION OF GENE EXPRESSION | 190 | 1493 | 1.29e-09 | 1.539e-07 |
40 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 139 | 1008 | 1.722e-09 | 2.003e-07 |
41 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 78 | 465 | 1.883e-09 | 2.137e-07 |
42 | REGULATION OF CELL ADHESION | 97 | 629 | 2.107e-09 | 2.334e-07 |
43 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 62 | 337 | 2.385e-09 | 2.581e-07 |
44 | REGULATION OF TRANSPORT | 220 | 1804 | 2.456e-09 | 2.597e-07 |
45 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 175 | 1360 | 2.735e-09 | 2.828e-07 |
46 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 232 | 1929 | 2.929e-09 | 2.939e-07 |
47 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 177 | 1381 | 2.969e-09 | 2.939e-07 |
48 | ORGAN MORPHOGENESIS | 120 | 841 | 3.213e-09 | 3.115e-07 |
49 | BLOOD VESSEL MORPHOGENESIS | 65 | 364 | 3.418e-09 | 3.246e-07 |
50 | REGULATION OF CELL PROJECTION ORGANIZATION | 88 | 558 | 3.992e-09 | 3.649e-07 |
51 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 81 | 498 | 4e-09 | 3.649e-07 |
52 | REGULATION OF CELL MORPHOGENESIS | 87 | 552 | 5.047e-09 | 4.517e-07 |
53 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 58 | 312 | 5.244e-09 | 4.604e-07 |
54 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 187 | 1492 | 5.833e-09 | 5.026e-07 |
55 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 235 | 1977 | 6.488e-09 | 5.489e-07 |
56 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 127 | 917 | 6.952e-09 | 5.777e-07 |
57 | PHOSPHORYLATION | 159 | 1228 | 1.018e-08 | 8.311e-07 |
58 | VESICLE MEDIATED TRANSPORT | 160 | 1239 | 1.095e-08 | 8.781e-07 |
59 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 188 | 1518 | 1.32e-08 | 1.041e-06 |
60 | REGULATION OF PROTEIN MODIFICATION PROCESS | 207 | 1710 | 1.425e-08 | 1.105e-06 |
61 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 101 | 689 | 1.481e-08 | 1.13e-06 |
62 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 113 | 799 | 1.546e-08 | 1.161e-06 |
63 | REGULATION OF CELL SUBSTRATE ADHESION | 38 | 173 | 2.517e-08 | 1.859e-06 |
64 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 219 | 1848 | 2.978e-08 | 2.143e-06 |
65 | CELL PROJECTION ORGANIZATION | 123 | 902 | 2.994e-08 | 2.143e-06 |
66 | REGULATION OF HYDROLASE ACTIVITY | 167 | 1327 | 3.13e-08 | 2.207e-06 |
67 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 128 | 957 | 4.844e-08 | 3.364e-06 |
68 | RESPONSE TO EXTERNAL STIMULUS | 215 | 1821 | 5.463e-08 | 3.738e-06 |
69 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 111 | 801 | 6.226e-08 | 4.198e-06 |
70 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 79 | 513 | 7.094e-08 | 4.715e-06 |
71 | POSITIVE REGULATION OF LOCOMOTION | 68 | 420 | 8.47e-08 | 5.551e-06 |
72 | NEGATIVE REGULATION OF CELL DEATH | 118 | 872 | 8.803e-08 | 5.689e-06 |
73 | SKELETAL SYSTEM DEVELOPMENT | 72 | 455 | 9.065e-08 | 5.778e-06 |
74 | REGULATION OF CELL DEATH | 179 | 1472 | 1.115e-07 | 7.01e-06 |
75 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 121 | 905 | 1.168e-07 | 7.247e-06 |
76 | UROGENITAL SYSTEM DEVELOPMENT | 53 | 299 | 1.209e-07 | 7.403e-06 |
77 | REGULATION OF GTPASE ACTIVITY | 96 | 673 | 1.276e-07 | 7.708e-06 |
78 | GROWTH | 66 | 410 | 1.629e-07 | 9.717e-06 |
79 | CELL GROWTH | 31 | 135 | 1.659e-07 | 9.772e-06 |
80 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 69 | 437 | 1.825e-07 | 1.062e-05 |
81 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 53 | 306 | 2.602e-07 | 1.495e-05 |
82 | ACTIN FILAMENT BASED PROCESS | 70 | 450 | 2.665e-07 | 1.512e-05 |
83 | TUBE MORPHOGENESIS | 55 | 323 | 2.761e-07 | 1.548e-05 |
84 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 116 | 872 | 2.804e-07 | 1.553e-05 |
85 | TELENCEPHALON DEVELOPMENT | 43 | 228 | 3.226e-07 | 1.766e-05 |
86 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 191 | 1618 | 3.376e-07 | 1.826e-05 |
87 | NEURON PROJECTION MORPHOGENESIS | 64 | 402 | 3.745e-07 | 2.003e-05 |
88 | NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 38 | 191 | 3.827e-07 | 2.024e-05 |
89 | TAXIS | 71 | 464 | 4.153e-07 | 2.171e-05 |
90 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 49 | 278 | 4.264e-07 | 2.205e-05 |
91 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 47 | 262 | 4.313e-07 | 2.205e-05 |
92 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 52 | 303 | 4.516e-07 | 2.284e-05 |
93 | REGULATION OF CYTOSKELETON ORGANIZATION | 75 | 502 | 5.134e-07 | 2.569e-05 |
94 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 43 | 232 | 5.296e-07 | 2.621e-05 |
95 | PROTEIN LOCALIZATION | 208 | 1805 | 5.653e-07 | 2.769e-05 |
96 | RESPONSE TO ESTROGEN | 41 | 218 | 6.49e-07 | 3.113e-05 |
97 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 75 | 505 | 6.49e-07 | 3.113e-05 |
98 | RESPONSE TO LIPID | 116 | 888 | 7.135e-07 | 3.388e-05 |
99 | NEGATIVE REGULATION OF CELL COMMUNICATION | 147 | 1192 | 7.43e-07 | 3.492e-05 |
100 | LEUKOCYTE DIFFERENTIATION | 50 | 292 | 7.998e-07 | 3.721e-05 |
101 | REGULATION OF KINASE ACTIVITY | 104 | 776 | 8.273e-07 | 3.776e-05 |
102 | POSITIVE REGULATION OF CELL PROLIFERATION | 108 | 814 | 8.277e-07 | 3.776e-05 |
103 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 141 | 1135 | 8.395e-07 | 3.792e-05 |
104 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 86 | 609 | 8.87e-07 | 3.968e-05 |
105 | IMMUNE SYSTEM DEVELOPMENT | 83 | 582 | 9.185e-07 | 4.07e-05 |
106 | REGULATION OF CATABOLIC PROCESS | 99 | 731 | 9.482e-07 | 4.162e-05 |
107 | CHEMICAL HOMEOSTASIS | 114 | 874 | 9.606e-07 | 4.177e-05 |
108 | CELLULAR RESPONSE TO LIPID | 69 | 457 | 9.902e-07 | 4.189e-05 |
109 | PALLIUM DEVELOPMENT | 32 | 153 | 9.903e-07 | 4.189e-05 |
110 | REGULATION OF ORGANELLE ORGANIZATION | 145 | 1178 | 9.889e-07 | 4.189e-05 |
111 | POSITIVE REGULATION OF CELL COMMUNICATION | 180 | 1532 | 1.038e-06 | 4.235e-05 |
112 | RESPONSE TO GROWTH FACTOR | 71 | 475 | 1.01e-06 | 4.235e-05 |
113 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 25 | 104 | 1.03e-06 | 4.235e-05 |
114 | REGULATION OF AXONOGENESIS | 34 | 168 | 1.024e-06 | 4.235e-05 |
115 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 51 | 303 | 1.059e-06 | 4.287e-05 |
116 | BIOLOGICAL ADHESION | 130 | 1032 | 1.102e-06 | 4.42e-05 |
117 | CELL PART MORPHOGENESIS | 88 | 633 | 1.291e-06 | 5.091e-05 |
118 | RESPONSE TO AMINO ACID | 26 | 112 | 1.289e-06 | 5.091e-05 |
119 | ESTABLISHMENT OF LOCALIZATION IN CELL | 193 | 1676 | 1.595e-06 | 6.236e-05 |
120 | NEURON PROJECTION DEVELOPMENT | 78 | 545 | 1.698e-06 | 6.583e-05 |
121 | EPITHELIUM DEVELOPMENT | 120 | 945 | 1.942e-06 | 7.469e-05 |
122 | ANGIOGENESIS | 49 | 293 | 2.068e-06 | 7.889e-05 |
123 | RESPONSE TO NITROGEN COMPOUND | 111 | 859 | 2.096e-06 | 7.928e-05 |
124 | POSITIVE REGULATION OF AXONOGENESIS | 19 | 69 | 2.303e-06 | 8.64e-05 |
125 | REGULATION OF CELLULAR LOCALIZATION | 153 | 1277 | 2.383e-06 | 8.87e-05 |
126 | HEAD DEVELOPMENT | 95 | 709 | 2.503e-06 | 9.243e-05 |
127 | SECOND MESSENGER MEDIATED SIGNALING | 32 | 160 | 2.75e-06 | 0.0001007 |
128 | TUBE DEVELOPMENT | 78 | 552 | 2.777e-06 | 0.0001009 |
129 | REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 14 | 41 | 3.045e-06 | 0.0001098 |
130 | RESPONSE TO WOUNDING | 79 | 563 | 3.142e-06 | 0.0001116 |
131 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 112 | 876 | 3.122e-06 | 0.0001116 |
132 | REGULATION OF CELL MATRIX ADHESION | 22 | 90 | 3.348e-06 | 0.000118 |
133 | REGULATION OF TRANSFERASE ACTIVITY | 119 | 946 | 3.407e-06 | 0.0001192 |
134 | POSITIVE REGULATION OF CELL ADHESION | 58 | 376 | 3.617e-06 | 0.0001256 |
135 | DEVELOPMENTAL GROWTH | 53 | 333 | 3.71e-06 | 0.0001279 |
136 | DENDRITE MORPHOGENESIS | 14 | 42 | 4.218e-06 | 0.0001443 |
137 | RESPONSE TO DRUG | 64 | 431 | 4.255e-06 | 0.0001445 |
138 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 55 | 352 | 4.332e-06 | 0.0001461 |
139 | ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 29 | 141 | 4.454e-06 | 0.0001491 |
140 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 100 | 767 | 4.584e-06 | 0.0001513 |
141 | RESPONSE TO HORMONE | 113 | 893 | 4.586e-06 | 0.0001513 |
142 | ORGANELLE LOCALIZATION | 62 | 415 | 4.906e-06 | 0.0001608 |
143 | REGULATION OF CELLULAR AMIDE METABOLIC PROCESS | 55 | 354 | 5.149e-06 | 0.0001675 |
144 | DENDRITE DEVELOPMENT | 20 | 79 | 5.202e-06 | 0.0001681 |
145 | RESPONSE TO ABIOTIC STIMULUS | 126 | 1024 | 5.315e-06 | 0.0001706 |
146 | MORPHOGENESIS OF AN EPITHELIUM | 60 | 400 | 6.106e-06 | 0.0001946 |
147 | AMINOGLYCAN METABOLIC PROCESS | 32 | 166 | 6.211e-06 | 0.0001966 |
148 | REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 15 | 49 | 6.375e-06 | 0.0002001 |
149 | ENDOCYTOSIS | 72 | 509 | 6.408e-06 | 0.0002001 |
150 | NEURON DEVELOPMENT | 91 | 687 | 6.512e-06 | 0.0002009 |
151 | REGULATION OF CELL CYCLE | 118 | 949 | 6.521e-06 | 0.0002009 |
152 | FOREBRAIN DEVELOPMENT | 55 | 357 | 6.646e-06 | 0.0002035 |
153 | REGULATION OF TRANSPORTER ACTIVITY | 36 | 198 | 6.81e-06 | 0.0002071 |
154 | NEURON DIFFERENTIATION | 110 | 874 | 7.844e-06 | 0.000237 |
155 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 56 | 368 | 8.002e-06 | 0.0002402 |
156 | REGULATION OF STEM CELL PROLIFERATION | 21 | 88 | 8.328e-06 | 0.0002484 |
157 | REGULATION OF AUTOPHAGY | 42 | 249 | 8.697e-06 | 0.0002577 |
158 | REGULATION OF MEMBRANE POTENTIAL | 53 | 343 | 8.908e-06 | 0.0002623 |
159 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 126 | 1036 | 9.396e-06 | 0.0002699 |
160 | CYTOSKELETON ORGANIZATION | 106 | 838 | 9.224e-06 | 0.0002699 |
161 | TISSUE MORPHOGENESIS | 74 | 533 | 9.347e-06 | 0.0002699 |
162 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 126 | 1036 | 9.396e-06 | 0.0002699 |
163 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 60 | 406 | 9.762e-06 | 0.0002787 |
164 | RESPONSE TO ALCOHOL | 55 | 362 | 1.007e-05 | 0.0002857 |
165 | LEUKOCYTE MIGRATION | 43 | 259 | 1.028e-05 | 0.0002898 |
166 | REGULATION OF VESICLE MEDIATED TRANSPORT | 66 | 462 | 1.114e-05 | 0.0003124 |
167 | REGULATION OF NEURON DEATH | 42 | 252 | 1.176e-05 | 0.0003278 |
168 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 120 | 983 | 1.295e-05 | 0.0003588 |
169 | DEVELOPMENTAL CELL GROWTH | 19 | 77 | 1.326e-05 | 0.000365 |
170 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 11 | 30 | 1.616e-05 | 0.0004397 |
171 | CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 11 | 30 | 1.616e-05 | 0.0004397 |
172 | ANION HOMEOSTASIS | 13 | 41 | 1.719e-05 | 0.0004624 |
173 | MESENCHYME DEVELOPMENT | 34 | 190 | 1.719e-05 | 0.0004624 |
174 | NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 15 | 53 | 1.839e-05 | 0.0004917 |
175 | POSITIVE REGULATION OF ENDOCYTOSIS | 24 | 114 | 1.922e-05 | 0.0005092 |
176 | RESPONSE TO NUTRIENT | 34 | 191 | 1.926e-05 | 0.0005092 |
177 | NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 28 | 144 | 1.952e-05 | 0.0005132 |
178 | AMINOGLYCAN BIOSYNTHETIC PROCESS | 23 | 107 | 1.997e-05 | 0.0005221 |
179 | POSITIVE REGULATION OF AXON EXTENSION | 12 | 36 | 2.048e-05 | 0.0005293 |
180 | LAMELLIPODIUM ORGANIZATION | 12 | 36 | 2.048e-05 | 0.0005293 |
181 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 33 | 184 | 2.166e-05 | 0.0005568 |
182 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 16 | 60 | 2.223e-05 | 0.0005684 |
183 | POSITIVE REGULATION OF TRANSPORT | 114 | 936 | 2.363e-05 | 0.0006008 |
184 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 45 | 285 | 2.392e-05 | 0.0006016 |
185 | REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 14 | 48 | 2.39e-05 | 0.0006016 |
186 | RESPONSE TO ESTRADIOL | 28 | 146 | 2.543e-05 | 0.0006361 |
187 | CELL ACTIVATION | 76 | 568 | 2.624e-05 | 0.000653 |
188 | CELL CHEMOTAXIS | 30 | 162 | 2.685e-05 | 0.0006646 |
189 | HEART DEVELOPMENT | 65 | 466 | 2.773e-05 | 0.0006814 |
190 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 16 | 61 | 2.783e-05 | 0.0006814 |
191 | ESTABLISHMENT OF CELL POLARITY | 20 | 88 | 2.916e-05 | 0.0007105 |
192 | MUSCLE CELL DIFFERENTIATION | 39 | 237 | 3.193e-05 | 0.0007738 |
193 | PEPTIDYL SERINE MODIFICATION | 28 | 148 | 3.291e-05 | 0.0007893 |
194 | POSITIVE REGULATION OF CELL GROWTH | 28 | 148 | 3.291e-05 | 0.0007893 |
195 | BONE DEVELOPMENT | 29 | 156 | 3.372e-05 | 0.0008005 |
196 | MUSCLE STRUCTURE DEVELOPMENT | 61 | 432 | 3.362e-05 | 0.0008005 |
197 | RESPONSE TO STEROID HORMONE | 68 | 497 | 3.406e-05 | 0.0008005 |
198 | REGULATION OF DEVELOPMENTAL GROWTH | 45 | 289 | 3.398e-05 | 0.0008005 |
199 | LYMPHOCYTE ACTIVATION | 51 | 342 | 3.466e-05 | 0.0008105 |
200 | RHYTHMIC PROCESS | 46 | 298 | 3.485e-05 | 0.0008109 |
201 | CELL CYCLE PHASE TRANSITION | 41 | 255 | 3.53e-05 | 0.0008157 |
202 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 76 | 573 | 3.541e-05 | 0.0008157 |
203 | CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS | 10 | 27 | 3.56e-05 | 0.0008161 |
204 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 42 | 264 | 3.678e-05 | 0.0008348 |
205 | REGULATION OF METAL ION TRANSPORT | 49 | 325 | 3.677e-05 | 0.0008348 |
206 | REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 12 | 38 | 3.786e-05 | 0.0008533 |
207 | MYELOID CELL DIFFERENTIATION | 33 | 189 | 3.796e-05 | 0.0008533 |
208 | CALCIUM MEDIATED SIGNALING | 20 | 90 | 4.116e-05 | 0.0009183 |
209 | REGULATION OF ANATOMICAL STRUCTURE SIZE | 65 | 472 | 4.125e-05 | 0.0009183 |
210 | REGULATION OF MUSCLE ADAPTATION | 16 | 63 | 4.285e-05 | 0.0009495 |
211 | REGULATION OF EPITHELIAL CELL MIGRATION | 30 | 166 | 4.333e-05 | 0.0009556 |
212 | EMBRYONIC MORPHOGENESIS | 72 | 539 | 4.478e-05 | 0.0009829 |
213 | CEREBRAL CORTEX DEVELOPMENT | 22 | 105 | 4.544e-05 | 0.0009926 |
214 | REGULATION OF CELLULAR COMPONENT SIZE | 50 | 337 | 4.706e-05 | 0.001023 |
215 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 87 | 684 | 4.744e-05 | 0.001027 |
216 | RESPONSE TO OXYGEN LEVELS | 47 | 311 | 4.948e-05 | 0.001066 |
217 | REGULATION OF HOMEOSTATIC PROCESS | 62 | 447 | 4.976e-05 | 0.001067 |
218 | REGULATION OF NEURON APOPTOTIC PROCESS | 33 | 192 | 5.246e-05 | 0.001115 |
219 | PROTEIN AUTOPHOSPHORYLATION | 33 | 192 | 5.246e-05 | 0.001115 |
220 | POSTTRANSCRIPTIONAL REGULATION OF GENE EXPRESSION | 62 | 448 | 5.316e-05 | 0.001119 |
221 | REGULATION OF CARDIAC MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 9 | 23 | 5.307e-05 | 0.001119 |
222 | OSSIFICATION | 40 | 251 | 5.359e-05 | 0.001123 |
223 | EPHRIN RECEPTOR SIGNALING PATHWAY | 19 | 85 | 5.836e-05 | 0.001212 |
224 | HEART PROCESS | 19 | 85 | 5.836e-05 | 0.001212 |
225 | NEGATIVE REGULATION OF PHOSPHORYLATION | 59 | 422 | 5.976e-05 | 0.001236 |
226 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 11 | 34 | 6.194e-05 | 0.001273 |
227 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 105 | 867 | 6.209e-05 | 0.001273 |
228 | CELL CYCLE | 149 | 1316 | 6.27e-05 | 0.00128 |
229 | CELLULAR MACROMOLECULE LOCALIZATION | 141 | 1234 | 6.462e-05 | 0.001313 |
230 | LEUKOCYTE ACTIVATION | 58 | 414 | 6.491e-05 | 0.001313 |
231 | EPITHELIAL CELL DEVELOPMENT | 32 | 186 | 6.633e-05 | 0.00133 |
232 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 64 | 470 | 6.61e-05 | 0.00133 |
233 | AMEBOIDAL TYPE CELL MIGRATION | 28 | 154 | 6.878e-05 | 0.001374 |
234 | MUCOPOLYSACCHARIDE METABOLIC PROCESS | 22 | 108 | 7.112e-05 | 0.001408 |
235 | NEGATIVE REGULATION OF CELL PROLIFERATION | 82 | 643 | 7.098e-05 | 0.001408 |
236 | REGULATION OF IMMUNE SYSTEM PROCESS | 157 | 1403 | 7.179e-05 | 0.001415 |
237 | NEGATIVE REGULATION OF LOCOMOTION | 41 | 263 | 7.237e-05 | 0.001421 |
238 | ION HOMEOSTASIS | 75 | 576 | 7.32e-05 | 0.001431 |
239 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 37 | 229 | 7.48e-05 | 0.001456 |
240 | REGULATION OF RESPONSE TO STRESS | 163 | 1468 | 7.757e-05 | 0.001504 |
241 | BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 9 | 24 | 7.864e-05 | 0.001506 |
242 | POSITIVE REGULATION OF GROWTH | 38 | 238 | 7.812e-05 | 0.001506 |
243 | NEGATIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 9 | 24 | 7.864e-05 | 0.001506 |
244 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 79 | 616 | 7.935e-05 | 0.001513 |
245 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 14 | 53 | 8.017e-05 | 0.001523 |
246 | REGULATION OF CELL SIZE | 30 | 172 | 8.545e-05 | 0.001616 |
247 | REGULATION OF RECEPTOR ACTIVITY | 23 | 117 | 8.766e-05 | 0.001651 |
248 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 110 | 926 | 9.192e-05 | 0.001725 |
249 | REGULATION OF WNT SIGNALING PATHWAY | 46 | 310 | 9.256e-05 | 0.00173 |
250 | RESPONSE TO ACID CHEMICAL | 47 | 319 | 9.3e-05 | 0.001731 |
251 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 158 | 1423 | 0.0001004 | 0.001859 |
252 | STEM CELL DIFFERENTIATION | 32 | 190 | 0.0001007 | 0.001859 |
253 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 21 | 103 | 0.0001016 | 0.001868 |
254 | SINGLE ORGANISM BEHAVIOR | 54 | 384 | 0.0001034 | 0.001894 |
255 | ACTIN FILAMENT ORGANIZATION | 30 | 174 | 0.0001061 | 0.001936 |
256 | MESENCHYMAL CELL DIFFERENTIATION | 25 | 134 | 0.0001075 | 0.001954 |
257 | REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 15 | 61 | 0.0001099 | 0.001989 |
258 | RESPONSE TO EXTRACELLULAR STIMULUS | 60 | 441 | 0.0001129 | 0.002028 |
259 | REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 19 | 89 | 0.0001127 | 0.002028 |
260 | REGULATION OF GROWTH | 80 | 633 | 0.0001169 | 0.00209 |
261 | NEURAL CREST CELL DIFFERENTIATION | 17 | 75 | 0.0001172 | 0.00209 |
262 | CELLULAR RESPONSE TO ACID CHEMICAL | 30 | 175 | 0.000118 | 0.002096 |
263 | POSITIVE REGULATION OF CELL DEATH | 77 | 605 | 0.0001245 | 0.002202 |
264 | LYMPHOCYTE DIFFERENTIATION | 34 | 209 | 0.0001253 | 0.002209 |
265 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 31 | 184 | 0.0001274 | 0.002238 |
266 | FOREBRAIN CELL MIGRATION | 15 | 62 | 0.0001339 | 0.002342 |
267 | REGULATION OF POTASSIUM ION TRANSPORT | 18 | 83 | 0.0001369 | 0.002385 |
268 | CELLULAR RESPONSE TO GLUCOSE STARVATION | 10 | 31 | 0.0001374 | 0.002385 |
269 | POSITIVE REGULATION OF KINASE ACTIVITY | 64 | 482 | 0.0001382 | 0.002391 |
270 | REGULATION OF MUSCLE HYPERTROPHY | 11 | 37 | 0.0001466 | 0.002516 |
271 | CARDIAC MUSCLE CELL ACTION POTENTIAL | 11 | 37 | 0.0001466 | 0.002516 |
272 | CELL CYCLE PROCESS | 124 | 1081 | 0.000152 | 0.0026 |
273 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 59 | 437 | 0.0001583 | 0.002697 |
274 | POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 7 | 16 | 0.0001615 | 0.002742 |
275 | REGULATION OF SODIUM ION TRANSPORT | 17 | 77 | 0.0001652 | 0.002785 |
276 | AGING | 40 | 264 | 0.0001647 | 0.002785 |
277 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 16 | 70 | 0.0001661 | 0.00279 |
278 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 20 | 99 | 0.0001678 | 0.002809 |
279 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 13 | 50 | 0.0001704 | 0.002842 |
280 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 25 | 138 | 0.0001746 | 0.002898 |
281 | REGULATION OF ION TRANSPORT | 75 | 592 | 0.000175 | 0.002898 |
282 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 71 | 554 | 0.0001828 | 0.003017 |
283 | NEGATIVE REGULATION OF NEURON DEATH | 29 | 171 | 0.0001843 | 0.00303 |
284 | CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS | 31 | 188 | 0.0001903 | 0.003116 |
285 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 124 | 1087 | 0.0001914 | 0.003116 |
286 | NEURON PROJECTION GUIDANCE | 33 | 205 | 0.0001915 | 0.003116 |
287 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 20 | 100 | 0.0001936 | 0.003138 |
288 | WOUND HEALING | 62 | 470 | 0.0002092 | 0.00338 |
289 | FEMALE SEX DIFFERENTIATION | 22 | 116 | 0.0002128 | 0.003426 |
290 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 27 | 156 | 0.0002151 | 0.00345 |
291 | REGULATION OF EXTENT OF CELL GROWTH | 20 | 101 | 0.0002227 | 0.003561 |
292 | REGULATION OF CARDIAC MUSCLE CELL CONTRACTION | 9 | 27 | 0.0002241 | 0.00357 |
293 | REGULATION OF ENDOCYTOSIS | 32 | 199 | 0.0002424 | 0.003849 |
294 | REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY | 8 | 22 | 0.0002538 | 0.003976 |
295 | POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 8 | 22 | 0.0002538 | 0.003976 |
296 | CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS | 8 | 22 | 0.0002538 | 0.003976 |
297 | POSITIVE REGULATION OF CARDIAC MUSCLE HYPERTROPHY | 8 | 22 | 0.0002538 | 0.003976 |
298 | HIPPOCAMPUS DEVELOPMENT | 16 | 73 | 0.0002782 | 0.004344 |
299 | REGULATION OF INTRACELLULAR TRANSPORT | 77 | 621 | 0.0002827 | 0.0044 |
300 | PEPTIDYL THREONINE MODIFICATION | 12 | 46 | 0.0002909 | 0.004512 |
301 | RESPONSE TO MECHANICAL STIMULUS | 33 | 210 | 0.000302 | 0.004669 |
302 | EMBRYO DEVELOPMENT | 104 | 894 | 0.0003092 | 0.004764 |
303 | POSITIVE REGULATION OF PROTEIN KINASE B SIGNALING | 17 | 81 | 0.0003145 | 0.00483 |
304 | NEURON PROJECTION EXTENSION | 13 | 53 | 0.0003192 | 0.004854 |
305 | MYELOID LEUKOCYTE DIFFERENTIATION | 19 | 96 | 0.0003188 | 0.004854 |
306 | CELLULAR MONOVALENT INORGANIC CATION HOMEOSTASIS | 19 | 96 | 0.0003188 | 0.004854 |
307 | RESPONSE TO FLUID SHEAR STRESS | 10 | 34 | 0.0003223 | 0.004885 |
308 | CARBOHYDRATE DERIVATIVE BIOSYNTHETIC PROCESS | 74 | 595 | 0.0003367 | 0.005081 |
309 | POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 26 | 152 | 0.0003374 | 0.005081 |
310 | DIVALENT INORGANIC ANION HOMEOSTASIS | 6 | 13 | 0.0003422 | 0.00512 |
311 | REGULATION OF CYTOPLASMIC TRANSLATION | 6 | 13 | 0.0003422 | 0.00512 |
312 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 25 | 144 | 0.0003449 | 0.005143 |
313 | PEPTIDYL TYROSINE MODIFICATION | 30 | 186 | 0.0003539 | 0.00526 |
314 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 76 | 616 | 0.0003589 | 0.005318 |
315 | POSITIVE REGULATION OF MAPK CASCADE | 61 | 470 | 0.0003623 | 0.005334 |
316 | POSITIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 12 | 47 | 0.0003613 | 0.005334 |
317 | CELL DEATH | 114 | 1001 | 0.0003672 | 0.00539 |
318 | ARTERY DEVELOPMENT | 16 | 75 | 0.0003849 | 0.005632 |
319 | ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 7 | 18 | 0.000387 | 0.005645 |
320 | OVULATION CYCLE | 21 | 113 | 0.000391 | 0.005686 |
321 | REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 33 | 213 | 0.0003928 | 0.005693 |
322 | REGULATION OF PROTEIN KINASE B SIGNALING | 22 | 121 | 0.0003954 | 0.005713 |
323 | REGULATION OF CELL JUNCTION ASSEMBLY | 15 | 68 | 0.0003969 | 0.005718 |
324 | PEPTIDYL AMINO ACID MODIFICATION | 98 | 841 | 0.0004311 | 0.006192 |
325 | CELL CYCLE G2 M PHASE TRANSITION | 24 | 138 | 0.000437 | 0.006256 |
326 | POSITIVE REGULATION OF HEMOPOIESIS | 27 | 163 | 0.0004445 | 0.006333 |
327 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 22 | 122 | 0.0004451 | 0.006333 |
328 | CELLULAR RESPONSE TO HORMONE STIMULUS | 69 | 552 | 0.0004571 | 0.006485 |
329 | WNT SIGNALING PATHWAY | 48 | 351 | 0.0004653 | 0.00658 |
330 | CELL PROLIFERATION | 81 | 672 | 0.0004832 | 0.006813 |
331 | REGULATION OF CELL CELL ADHESION | 51 | 380 | 0.0004913 | 0.006906 |
332 | POSITIVE REGULATION OF OSSIFICATION | 17 | 84 | 0.0004927 | 0.006906 |
333 | NEGATIVE REGULATION OF CELLULAR AMIDE METABOLIC PROCESS | 23 | 131 | 0.0004957 | 0.006906 |
334 | PROTEIN STABILIZATION | 23 | 131 | 0.0004957 | 0.006906 |
335 | CELLULAR RESPONSE TO ALCOHOL | 21 | 115 | 0.0004994 | 0.006936 |
336 | ACTIN NUCLEATION | 8 | 24 | 0.0005019 | 0.006951 |
337 | STRIATED MUSCLE CELL DIFFERENTIATION | 28 | 173 | 0.0005169 | 0.007137 |
338 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 86 | 724 | 0.0005236 | 0.007207 |
339 | REGULATION OF NUCLEOTIDE CATABOLIC PROCESS | 10 | 36 | 0.0005357 | 0.007353 |
340 | RESPONSE TO EPIDERMAL GROWTH FACTOR | 9 | 30 | 0.0005441 | 0.007379 |
341 | NEGATIVE REGULATION OF CELL MATRIX ADHESION | 9 | 30 | 0.0005441 | 0.007379 |
342 | LIMBIC SYSTEM DEVELOPMENT | 19 | 100 | 0.0005456 | 0.007379 |
343 | SINGLE ORGANISM CELLULAR LOCALIZATION | 103 | 898 | 0.0005441 | 0.007379 |
344 | LAMELLIPODIUM ASSEMBLY | 9 | 30 | 0.0005441 | 0.007379 |
345 | MITOTIC CELL CYCLE | 90 | 766 | 0.0005598 | 0.007501 |
346 | MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 14 | 0.0005567 | 0.007501 |
347 | INOSITOL LIPID MEDIATED SIGNALING | 22 | 124 | 0.000561 | 0.007501 |
348 | RESPONSE TO REACTIVE OXYGEN SPECIES | 30 | 191 | 0.0005592 | 0.007501 |
349 | REGULATION OF CARDIAC MUSCLE CELL ACTION POTENTIAL | 7 | 19 | 0.0005688 | 0.00754 |
350 | CELLULAR SODIUM ION HOMEOSTASIS | 7 | 19 | 0.0005688 | 0.00754 |
351 | MONOVALENT INORGANIC ANION HOMEOSTASIS | 7 | 19 | 0.0005688 | 0.00754 |
352 | ACTIN FILAMENT BASED MOVEMENT | 18 | 93 | 0.0006002 | 0.007911 |
353 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 33 | 218 | 0.0005985 | 0.007911 |
354 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 35 | 236 | 0.0006108 | 0.007984 |
355 | POSITIVE REGULATION OF ION TRANSPORT | 35 | 236 | 0.0006108 | 0.007984 |
356 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 16 | 78 | 0.0006104 | 0.007984 |
357 | CEREBRAL CORTEX CELL MIGRATION | 11 | 43 | 0.0006191 | 0.008047 |
358 | CHONDROITIN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 11 | 43 | 0.0006191 | 0.008047 |
359 | GLIOGENESIS | 28 | 175 | 0.0006235 | 0.008059 |
360 | RESPONSE TO PURINE CONTAINING COMPOUND | 26 | 158 | 0.0006223 | 0.008059 |
361 | KIDNEY EPITHELIUM DEVELOPMENT | 22 | 125 | 0.0006282 | 0.008097 |
362 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 27 | 167 | 0.0006553 | 0.008424 |
363 | REGULATION OF CYTOPLASMIC TRANSPORT | 61 | 481 | 0.0006603 | 0.008464 |
364 | AXON EXTENSION | 10 | 37 | 0.0006798 | 0.00869 |
365 | CELLULAR RESPONSE TO EPIDERMAL GROWTH FACTOR STIMULUS | 8 | 25 | 0.0006846 | 0.008703 |
366 | REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 8 | 25 | 0.0006846 | 0.008703 |
367 | REGULATION OF MAPK CASCADE | 79 | 660 | 0.0006938 | 0.008796 |
368 | RAS PROTEIN SIGNAL TRANSDUCTION | 24 | 143 | 0.0007421 | 0.009383 |
369 | MUSCLE TISSUE DEVELOPMENT | 39 | 275 | 0.0007554 | 0.009525 |
370 | HOMEOSTATIC PROCESS | 144 | 1337 | 0.0007626 | 0.009572 |
371 | REGULATION OF PROTEIN STABILITY | 33 | 221 | 0.0007632 | 0.009572 |
372 | REGULATION OF MUSCLE SYSTEM PROCESS | 30 | 195 | 0.0007925 | 0.009913 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYTOSKELETAL PROTEIN BINDING | 134 | 819 | 1.679e-14 | 1.56e-11 |
2 | ENZYME BINDING | 230 | 1737 | 2.997e-13 | 1.392e-10 |
3 | MACROMOLECULAR COMPLEX BINDING | 192 | 1399 | 1.476e-12 | 4.571e-10 |
4 | PROTEIN COMPLEX BINDING | 139 | 935 | 9.012e-12 | 2.093e-09 |
5 | RIBONUCLEOTIDE BINDING | 233 | 1860 | 5.939e-11 | 1.103e-08 |
6 | PROTEIN KINASE ACTIVITY | 101 | 640 | 2.667e-10 | 4.13e-08 |
7 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 62 | 328 | 7.876e-10 | 1.045e-07 |
8 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 97 | 629 | 2.107e-09 | 2.447e-07 |
9 | KINASE ACTIVITY | 119 | 842 | 6.582e-09 | 6.794e-07 |
10 | ADENYL NUCLEOTIDE BINDING | 188 | 1514 | 1.08e-08 | 1.003e-06 |
11 | ACTIN BINDING | 67 | 393 | 1.355e-08 | 1.144e-06 |
12 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 57 | 315 | 1.929e-08 | 1.493e-06 |
13 | KINASE BINDING | 91 | 606 | 2.466e-08 | 1.762e-06 |
14 | REGULATORY REGION NUCLEIC ACID BINDING | 114 | 818 | 3.012e-08 | 1.999e-06 |
15 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 72 | 445 | 3.642e-08 | 2.255e-06 |
16 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 44 | 226 | 9.176e-08 | 5.328e-06 |
17 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 129 | 992 | 2.147e-07 | 1.173e-05 |
18 | RECEPTOR BINDING | 177 | 1476 | 3.398e-07 | 1.753e-05 |
19 | MICROTUBULE BINDING | 39 | 201 | 5.307e-07 | 2.595e-05 |
20 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 84 | 588 | 7.354e-07 | 3.416e-05 |
21 | MOLECULAR FUNCTION REGULATOR | 162 | 1353 | 1.226e-06 | 5.324e-05 |
22 | DOUBLE STRANDED DNA BINDING | 102 | 764 | 1.261e-06 | 5.324e-05 |
23 | TRANSCRIPTION FACTOR BINDING | 76 | 524 | 1.383e-06 | 5.586e-05 |
24 | TUBULIN BINDING | 47 | 273 | 1.449e-06 | 5.61e-05 |
25 | SEQUENCE SPECIFIC DNA BINDING | 129 | 1037 | 2.342e-06 | 8.419e-05 |
26 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 58 | 371 | 2.356e-06 | 8.419e-05 |
27 | TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 33 | 168 | 2.925e-06 | 0.0001006 |
28 | PROTEIN DIMERIZATION ACTIVITY | 138 | 1149 | 6.726e-06 | 0.0002232 |
29 | PROTEIN DOMAIN SPECIFIC BINDING | 84 | 624 | 7.958e-06 | 0.0002549 |
30 | ENHANCER BINDING | 21 | 93 | 2.064e-05 | 0.0006244 |
31 | ENZYME ACTIVATOR ACTIVITY | 66 | 471 | 2.084e-05 | 0.0006244 |
32 | NUCLEOSIDE TRIPHOSPHATASE REGULATOR ACTIVITY | 50 | 329 | 2.484e-05 | 0.0006993 |
33 | GLYCOPROTEIN BINDING | 22 | 101 | 2.414e-05 | 0.0006993 |
34 | CALMODULIN BINDING | 32 | 179 | 3.062e-05 | 0.0008367 |
35 | IDENTICAL PROTEIN BINDING | 140 | 1209 | 3.631e-05 | 0.0009638 |
36 | PROTEIN HOMODIMERIZATION ACTIVITY | 91 | 722 | 4.504e-05 | 0.001162 |
37 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 138 | 1199 | 5.514e-05 | 0.00138 |
38 | GROWTH FACTOR RECEPTOR BINDING | 25 | 129 | 5.644e-05 | 0.00138 |
39 | TRANSCRIPTION COACTIVATOR ACTIVITY | 45 | 296 | 6.133e-05 | 0.001461 |
40 | NITRIC OXIDE SYNTHASE BINDING | 8 | 19 | 7.528e-05 | 0.001748 |
41 | STEROID HORMONE RECEPTOR BINDING | 18 | 81 | 9.817e-05 | 0.002224 |
42 | MRNA 3 UTR BINDING | 13 | 48 | 0.0001084 | 0.002398 |
43 | TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 21 | 105 | 0.0001354 | 0.002925 |
44 | ENZYME REGULATOR ACTIVITY | 112 | 959 | 0.0001573 | 0.003321 |
45 | SODIUM CHANNEL REGULATOR ACTIVITY | 10 | 32 | 0.000185 | 0.003819 |
46 | ANDROGEN RECEPTOR BINDING | 11 | 39 | 0.000246 | 0.004967 |
47 | ION CHANNEL BINDING | 21 | 111 | 0.0003038 | 0.005921 |
48 | CALMODULIN DEPENDENT PROTEIN KINASE ACTIVITY | 9 | 28 | 0.0003059 | 0.005921 |
49 | LIGAND DEPENDENT NUCLEAR RECEPTOR TRANSCRIPTION COACTIVATOR ACTIVITY | 13 | 53 | 0.0003192 | 0.006052 |
50 | CORE PROMOTER BINDING | 26 | 152 | 0.0003374 | 0.006269 |
51 | SNARE BINDING | 23 | 128 | 0.000352 | 0.006413 |
52 | SYNTAXIN 1 BINDING | 7 | 18 | 0.000387 | 0.006914 |
53 | ACTIN FILAMENT BINDING | 22 | 121 | 0.0003954 | 0.006919 |
54 | PHOSPHATASE BINDING | 27 | 162 | 0.0004022 | 0.006919 |
55 | ATPASE BINDING | 16 | 76 | 0.0004504 | 0.007608 |
56 | GUANYL NUCLEOTIDE BINDING | 52 | 390 | 0.0005082 | 0.008284 |
57 | EPHRIN RECEPTOR BINDING | 8 | 24 | 0.0005019 | 0.008284 |
58 | PHOSPHATIDYLINOSITOL 3 KINASE BINDING | 9 | 30 | 0.0005441 | 0.008714 |
59 | SYNTAXIN BINDING | 18 | 93 | 0.0006002 | 0.00945 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELL JUNCTION | 177 | 1151 | 3.668e-16 | 2.142e-13 |
2 | ANCHORING JUNCTION | 92 | 489 | 8.099e-14 | 2.365e-11 |
3 | CELL SUBSTRATE JUNCTION | 79 | 398 | 2.682e-13 | 5.22e-11 |
4 | CELL PROJECTION | 232 | 1786 | 1.734e-12 | 2.532e-10 |
5 | MEMBRANE REGION | 157 | 1134 | 1.032e-10 | 1.206e-08 |
6 | NEURON PROJECTION | 134 | 942 | 4.526e-10 | 3.837e-08 |
7 | GOLGI APPARATUS | 187 | 1445 | 4.599e-10 | 3.837e-08 |
8 | NEURON PART | 166 | 1265 | 1.76e-09 | 1.285e-07 |
9 | GOLGI APPARATUS PART | 124 | 893 | 9.046e-09 | 5.87e-07 |
10 | CELL CELL JUNCTION | 66 | 383 | 1.126e-08 | 6.576e-07 |
11 | SYNAPSE | 108 | 754 | 1.645e-08 | 8.736e-07 |
12 | CELL LEADING EDGE | 61 | 350 | 2.624e-08 | 1.277e-06 |
13 | CYTOSKELETON | 227 | 1967 | 1.408e-07 | 6.117e-06 |
14 | GOLGI MEMBRANE | 99 | 703 | 1.513e-07 | 6.117e-06 |
15 | PLASMA MEMBRANE REGION | 123 | 929 | 1.571e-07 | 6.117e-06 |
16 | INTRACELLULAR VESICLE | 155 | 1259 | 4.034e-07 | 1.472e-05 |
17 | ACTIN CYTOSKELETON | 68 | 444 | 7.029e-07 | 2.415e-05 |
18 | MICROTUBULE | 63 | 405 | 1.044e-06 | 3.388e-05 |
19 | MEMBRANE MICRODOMAIN | 49 | 288 | 1.244e-06 | 3.823e-05 |
20 | COATED PIT | 19 | 67 | 1.413e-06 | 4.126e-05 |
21 | SOMATODENDRITIC COMPARTMENT | 89 | 650 | 2.134e-06 | 5.935e-05 |
22 | CELL CELL CONTACT ZONE | 18 | 64 | 3.033e-06 | 8.039e-05 |
23 | COATED VESICLE MEMBRANE | 29 | 139 | 3.304e-06 | 8.039e-05 |
24 | SYNAPSE PART | 84 | 610 | 3.283e-06 | 8.039e-05 |
25 | COATED VESICLE | 41 | 234 | 4.241e-06 | 9.906e-05 |
26 | DENDRITE | 66 | 451 | 4.986e-06 | 0.000112 |
27 | VACUOLE | 141 | 1180 | 6.962e-06 | 0.0001506 |
28 | POSTSYNAPSE | 57 | 378 | 8.805e-06 | 0.0001837 |
29 | CELL PROJECTION PART | 117 | 946 | 9.158e-06 | 0.0001844 |
30 | TRANS GOLGI NETWORK | 35 | 193 | 9.637e-06 | 0.0001876 |
31 | ENDOSOME | 101 | 793 | 1.123e-05 | 0.0002055 |
32 | ORGANELLE SUBCOMPARTMENT | 49 | 311 | 1.126e-05 | 0.0002055 |
33 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 183 | 1649 | 2.833e-05 | 0.0005014 |
34 | CYTOSKELETAL PART | 162 | 1436 | 3.59e-05 | 0.0006167 |
35 | EXCITATORY SYNAPSE | 34 | 197 | 3.73e-05 | 0.0006224 |
36 | ENDOCYTIC VESICLE | 41 | 256 | 3.871e-05 | 0.000628 |
37 | INTERCALATED DISC | 14 | 51 | 5.05e-05 | 0.0007563 |
38 | APICAL JUNCTION COMPLEX | 25 | 128 | 4.935e-05 | 0.0007563 |
39 | BASAL PART OF CELL | 14 | 51 | 5.05e-05 | 0.0007563 |
40 | CYTOPLASMIC REGION | 44 | 287 | 6.022e-05 | 0.0008792 |
41 | MEMBRANE PROTEIN COMPLEX | 120 | 1020 | 6.744e-05 | 0.0009605 |
42 | LAMELLIPODIUM | 30 | 172 | 8.545e-05 | 0.001181 |
43 | RUFFLE | 28 | 156 | 8.693e-05 | 0.001181 |
44 | CLATHRIN COATED VESICLE | 28 | 157 | 9.752e-05 | 0.001274 |
45 | CLATHRIN COATED VESICLE MEMBRANE | 18 | 81 | 9.817e-05 | 0.001274 |
46 | ARP2 3 PROTEIN COMPLEX | 6 | 11 | 0.0001067 | 0.001354 |
47 | KINESIN COMPLEX | 14 | 55 | 0.000124 | 0.00154 |
48 | BASOLATERAL PLASMA MEMBRANE | 34 | 211 | 0.0001514 | 0.001804 |
49 | NEURON SPINE | 23 | 121 | 0.0001492 | 0.001804 |
50 | CELL CORTEX | 37 | 238 | 0.0001684 | 0.001967 |
51 | CLATHRIN COATED ENDOCYTIC VESICLE | 15 | 65 | 0.0002352 | 0.002694 |
52 | VESICLE MEMBRANE | 66 | 512 | 0.0002578 | 0.002895 |
53 | CYTOPLASMIC VESICLE PART | 75 | 601 | 0.000278 | 0.003063 |
54 | CELL PROJECTION MEMBRANE | 43 | 298 | 0.0002873 | 0.003107 |
55 | VACUOLAR PART | 84 | 694 | 0.0003356 | 0.003563 |
56 | EARLY ENDOSOME | 43 | 301 | 0.0003572 | 0.003725 |
57 | MICROTUBULE ASSOCIATED COMPLEX | 25 | 145 | 0.0003843 | 0.003938 |
58 | COSTAMERE | 7 | 19 | 0.0005688 | 0.005727 |
59 | ER TO GOLGI TRANSPORT VESICLE | 15 | 71 | 0.0006457 | 0.005985 |
60 | MICROTUBULE CYTOSKELETON | 119 | 1068 | 0.0006366 | 0.005985 |
61 | NUCLEAR CHROMATIN | 41 | 291 | 0.0006417 | 0.005985 |
62 | EXTRACELLULAR MATRIX COMPONENT | 22 | 125 | 0.0006282 | 0.005985 |
63 | SARCOLEMMA | 22 | 125 | 0.0006282 | 0.005985 |
64 | SUPRAMOLECULAR FIBER | 80 | 670 | 0.0006925 | 0.006319 |
65 | BRUSH BORDER | 19 | 102 | 0.0007038 | 0.006324 |
66 | CELL DIVISION SITE | 12 | 52 | 0.0009668 | 0.008555 |
67 | PLASMA MEMBRANE PROTEIN COMPLEX | 63 | 510 | 0.001067 | 0.009304 |
68 | GLYCOPROTEIN COMPLEX | 7 | 21 | 0.001132 | 0.009719 |
69 | BASAL PLASMA MEMBRANE | 9 | 33 | 0.001167 | 0.00988 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04510_Focal_adhesion | 41 | 387 | 0.06702 | 1 | |
2 | hsa04010_MAPK_signaling_pathway | 38 | 387 | 0.1655 | 1 | |
3 | hsa04810_Regulation_of_actin_cytoskeleton | 35 | 387 | 0.3324 | 1 | |
4 | hsa04144_Endocytosis | 34 | 387 | 0.401 | 1 | |
5 | hsa04020_Calcium_signaling_pathway | 29 | 387 | 0.7544 | 1 | |
6 | hsa04062_Chemokine_signaling_pathway | 28 | 387 | 0.8111 | 1 | |
7 | hsa04360_Axon_guidance | 27 | 387 | 0.8593 | 1 | |
8 | hsa04114_Oocyte_meiosis | 23 | 387 | 0.9701 | 1 | |
9 | hsa04310_Wnt_signaling_pathway | 23 | 387 | 0.9701 | 1 | |
10 | hsa04530_Tight_junction | 23 | 387 | 0.9701 | 1 | |
11 | hsa04630_Jak.STAT_signaling_pathway | 22 | 387 | 0.9817 | 1 | |
12 | hsa04972_Pancreatic_secretion | 22 | 387 | 0.9817 | 1 | |
13 | hsa04514_Cell_adhesion_molecules_.CAMs. | 21 | 387 | 0.9893 | 1 | |
14 | hsa04670_Leukocyte_transendothelial_migration | 21 | 387 | 0.9893 | 1 | |
15 | hsa00230_Purine_metabolism | 20 | 387 | 0.994 | 1 | |
16 | hsa04540_Gap_junction | 19 | 387 | 0.9968 | 1 | |
17 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 19 | 387 | 0.9968 | 1 | |
18 | hsa04912_GnRH_signaling_pathway | 19 | 387 | 0.9968 | 1 | |
19 | hsa04916_Melanogenesis | 19 | 387 | 0.9968 | 1 | |
20 | hsa04971_Gastric_acid_secretion | 19 | 387 | 0.9968 | 1 | |
21 | hsa04120_Ubiquitin_mediated_proteolysis | 18 | 387 | 0.9984 | 1 | |
22 | hsa04270_Vascular_smooth_muscle_contraction | 18 | 387 | 0.9984 | 1 | |
23 | hsa04012_ErbB_signaling_pathway | 17 | 387 | 0.9993 | 1 | |
24 | hsa04722_Neurotrophin_signaling_pathway | 17 | 387 | 0.9993 | 1 | |
25 | hsa04970_Salivary_secretion | 17 | 387 | 0.9993 | 1 | |
26 | hsa04974_Protein_digestion_and_absorption | 16 | 387 | 0.9997 | 1 | |
27 | hsa04110_Cell_cycle | 14 | 387 | 0.9999 | 1 | |
28 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 14 | 387 | 0.9999 | 1 | |
29 | hsa04520_Adherens_junction | 14 | 387 | 0.9999 | 1 | |
30 | hsa04660_T_cell_receptor_signaling_pathway | 15 | 387 | 0.9999 | 1 | |
31 | hsa04720_Long.term_potentiation | 14 | 387 | 0.9999 | 1 | |
32 | hsa04910_Insulin_signaling_pathway | 14 | 387 | 0.9999 | 1 | |
33 | hsa04914_Progesterone.mediated_oocyte_maturation | 15 | 387 | 0.9999 | 1 | |
34 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 14 | 387 | 0.9999 | 1 | |
35 | hsa00010_Glycolysis_._Gluconeogenesis | 5 | 387 | 1 | 1 | |
36 | hsa00020_Citrate_cycle_.TCA_cycle. | 5 | 387 | 1 | 1 | |
37 | hsa00030_Pentose_phosphate_pathway | 4 | 387 | 1 | 1 | |
38 | hsa00040_Pentose_and_glucuronate_interconversions | 2 | 387 | 1 | 1 | |
39 | hsa00051_Fructose_and_mannose_metabolism | 2 | 387 | 1 | 1 | |
40 | hsa00053_Ascorbate_and_aldarate_metabolism | 2 | 387 | 1 | 1 | |
41 | hsa00071_Fatty_acid_metabolism | 4 | 387 | 1 | 1 | |
42 | hsa00140_Steroid_hormone_biosynthesis | 6 | 387 | 1 | 1 | |
43 | hsa00190_Oxidative_phosphorylation | 5 | 387 | 1 | 1 | |
44 | hsa00240_Pyrimidine_metabolism | 8 | 387 | 1 | 1 | |
45 | hsa00250_Alanine._aspartate_and_glutamate_metabolism | 2 | 387 | 1 | 1 | |
46 | hsa00260_Glycine._serine_and_threonine_metabolism | 3 | 387 | 1 | 1 | |
47 | hsa00280_Valine._leucine_and_isoleucine_degradation | 5 | 387 | 1 | 1 | |
48 | hsa00290_Valine._leucine_and_isoleucine_biosynthesis | 2 | 387 | 1 | 1 | |
49 | hsa00310_Lysine_degradation | 3 | 387 | 1 | 1 | |
50 | hsa00340_Histidine_metabolism | 3 | 387 | 1 | 1 | |
51 | hsa00350_Tyrosine_metabolism | 4 | 387 | 1 | 1 | |
52 | hsa00380_Tryptophan_metabolism | 2 | 387 | 1 | 1 | |
53 | hsa00410_beta.Alanine_metabolism | 2 | 387 | 1 | 1 | |
54 | hsa00450_Selenocompound_metabolism | 2 | 387 | 1 | 1 | |
55 | hsa00480_Glutathione_metabolism | 2 | 387 | 1 | 1 | |
56 | hsa00500_Starch_and_sucrose_metabolism | 4 | 387 | 1 | 1 | |
57 | hsa00510_N.Glycan_biosynthesis | 6 | 387 | 1 | 1 | |
58 | hsa00511_Other_glycan_degradation | 2 | 387 | 1 | 1 | |
59 | hsa00512_Mucin_type_O.Glycan_biosynthesis | 5 | 387 | 1 | 1 | |
60 | hsa00514_Other_types_of_O.glycan_biosynthesis | 4 | 387 | 1 | 1 | |
61 | hsa00520_Amino_sugar_and_nucleotide_sugar_metabolism | 6 | 387 | 1 | 1 | |
62 | hsa00531_Glycosaminoglycan_degradation | 2 | 387 | 1 | 1 | |
63 | hsa00532_Glycosaminoglycan_biosynthesis_._chondroitin_sulfate | 5 | 387 | 1 | 1 | |
64 | hsa00534_Glycosaminoglycan_biosynthesis_._heparan_sulfate | 5 | 387 | 1 | 1 | |
65 | hsa00561_Glycerolipid_metabolism | 3 | 387 | 1 | 1 | |
66 | hsa00562_Inositol_phosphate_metabolism | 5 | 387 | 1 | 1 | |
67 | hsa00563_Glycosylphosphatidylinositol.GPI..anchor_biosynthesis | 2 | 387 | 1 | 1 | |
68 | hsa00564_Glycerophospholipid_metabolism | 7 | 387 | 1 | 1 | |
69 | hsa00565_Ether_lipid_metabolism | 3 | 387 | 1 | 1 | |
70 | hsa00590_Arachidonic_acid_metabolism | 2 | 387 | 1 | 1 | |
71 | hsa00600_Sphingolipid_metabolism | 2 | 387 | 1 | 1 | |
72 | hsa00601_Glycosphingolipid_biosynthesis_._lacto_and_neolacto_series | 2 | 387 | 1 | 1 | |
73 | hsa00603_Glycosphingolipid_biosynthesis_._globo_series | 2 | 387 | 1 | 1 | |
74 | hsa00630_Glyoxylate_and_dicarboxylate_metabolism | 2 | 387 | 1 | 1 | |
75 | hsa00640_Propanoate_metabolism | 3 | 387 | 1 | 1 | |
76 | hsa00670_One_carbon_pool_by_folate | 2 | 387 | 1 | 1 | |
77 | hsa00750_Vitamin_B6_metabolism | 2 | 387 | 1 | 1 | |
78 | hsa00760_Nicotinate_and_nicotinamide_metabolism | 3 | 387 | 1 | 1 | |
79 | hsa00770_Pantothenate_and_CoA_biosynthesis | 5 | 387 | 1 | 1 | |
80 | hsa00830_Retinol_metabolism | 4 | 387 | 1 | 1 | |
81 | hsa00860_Porphyrin_and_chlorophyll_metabolism | 3 | 387 | 1 | 1 | |
82 | hsa00900_Terpenoid_backbone_biosynthesis | 2 | 387 | 1 | 1 | |
83 | hsa00910_Nitrogen_metabolism | 2 | 387 | 1 | 1 | |
84 | hsa00920_Sulfur_metabolism | 2 | 387 | 1 | 1 | |
85 | hsa00970_Aminoacyl.tRNA_biosynthesis | 3 | 387 | 1 | 1 | |
86 | hsa00980_Metabolism_of_xenobiotics_by_cytochrome_P450 | 3 | 387 | 1 | 1 | |
87 | hsa00982_Drug_metabolism_._cytochrome_P450 | 3 | 387 | 1 | 1 | |
88 | hsa00983_Drug_metabolism_._other_enzymes | 5 | 387 | 1 | 1 | |
89 | hsa01040_Biosynthesis_of_unsaturated_fatty_acids | 2 | 387 | 1 | 1 | |
90 | hsa02010_ABC_transporters | 7 | 387 | 1 | 1 | |
91 | hsa03008_Ribosome_biogenesis_in_eukaryotes | 8 | 387 | 1 | 1 | |
92 | hsa03013_RNA_transport | 6 | 387 | 1 | 1 | |
93 | hsa03015_mRNA_surveillance_pathway | 10 | 387 | 1 | 1 | |
94 | hsa03018_RNA_degradation | 3 | 387 | 1 | 1 | |
95 | hsa03020_RNA_polymerase | 2 | 387 | 1 | 1 | |
96 | hsa03022_Basal_transcription_factors | 2 | 387 | 1 | 1 | |
97 | hsa03040_Spliceosome | 4 | 387 | 1 | 1 | |
98 | hsa03050_Proteasome | 2 | 387 | 1 | 1 | |
99 | hsa03320_PPAR_signaling_pathway | 7 | 387 | 1 | 1 | |
100 | hsa03420_Nucleotide_excision_repair | 2 | 387 | 1 | 1 | |
101 | hsa03430_Mismatch_repair | 2 | 387 | 1 | 1 | |
102 | hsa04070_Phosphatidylinositol_signaling_system | 10 | 387 | 1 | 1 | |
103 | hsa04115_p53_signaling_pathway | 13 | 387 | 1 | 1 | |
104 | hsa04130_SNARE_interactions_in_vesicular_transport | 7 | 387 | 1 | 1 | |
105 | hsa04140_Regulation_of_autophagy | 4 | 387 | 1 | 1 | |
106 | hsa04142_Lysosome | 12 | 387 | 1 | 1 | |
107 | hsa04145_Phagosome | 13 | 387 | 1 | 1 | |
108 | hsa04146_Peroxisome | 9 | 387 | 1 | 1 | |
109 | hsa04150_mTOR_signaling_pathway | 10 | 387 | 1 | 1 | |
110 | hsa04210_Apoptosis | 13 | 387 | 1 | 1 | |
111 | hsa04260_Cardiac_muscle_contraction | 10 | 387 | 1 | 1 | |
112 | hsa04320_Dorso.ventral_axis_formation | 5 | 387 | 1 | 1 | |
113 | hsa04330_Notch_signaling_pathway | 2 | 387 | 1 | 1 | |
114 | hsa04340_Hedgehog_signaling_pathway | 7 | 387 | 1 | 1 | |
115 | hsa04350_TGF.beta_signaling_pathway | 10 | 387 | 1 | 1 | |
116 | hsa04370_VEGF_signaling_pathway | 11 | 387 | 1 | 1 | |
117 | hsa04380_Osteoclast_differentiation | 12 | 387 | 1 | 1 | |
118 | hsa04512_ECM.receptor_interaction | 13 | 387 | 1 | 1 | |
119 | hsa04610_Complement_and_coagulation_cascades | 2 | 387 | 1 | 1 | |
120 | hsa04612_Antigen_processing_and_presentation | 8 | 387 | 1 | 1 | |
121 | hsa04614_Renin.angiotensin_system | 2 | 387 | 1 | 1 | |
122 | hsa04620_Toll.like_receptor_signaling_pathway | 11 | 387 | 1 | 1 | |
123 | hsa04621_NOD.like_receptor_signaling_pathway | 6 | 387 | 1 | 1 | |
124 | hsa04622_RIG.I.like_receptor_signaling_pathway | 2 | 387 | 1 | 1 | |
125 | hsa04623_Cytosolic_DNA.sensing_pathway | 3 | 387 | 1 | 1 | |
126 | hsa04640_Hematopoietic_cell_lineage | 13 | 387 | 1 | 1 | |
127 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 12 | 387 | 1 | 1 | |
128 | hsa04662_B_cell_receptor_signaling_pathway | 11 | 387 | 1 | 1 | |
129 | hsa04664_Fc_epsilon_RI_signaling_pathway | 9 | 387 | 1 | 1 | |
130 | hsa04672_Intestinal_immune_network_for_IgA_production | 2 | 387 | 1 | 1 | |
131 | hsa04710_Circadian_rhythm_._mammal | 6 | 387 | 1 | 1 | |
132 | hsa04730_Long.term_depression | 12 | 387 | 1 | 1 | |
133 | hsa04740_Olfactory_transduction | 7 | 388 | 1 | 1 | |
134 | hsa04742_Taste_transduction | 2 | 387 | 1 | 1 | |
135 | hsa04920_Adipocytokine_signaling_pathway | 8 | 387 | 1 | 1 | |
136 | hsa04962_Vasopressin.regulated_water_reabsorption | 9 | 387 | 1 | 1 | |
137 | hsa04964_Proximal_tubule_bicarbonate_reclamation | 4 | 387 | 1 | 1 | |
138 | hsa04966_Collecting_duct_acid_secretion | 3 | 387 | 1 | 1 | |
139 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 387 | 1 | 1 | |
140 | hsa04976_Bile_secretion | 13 | 387 | 1 | 1 |